Aranesp vs Jynarque
Side-by-side cost comparison based on Medicare Part D data
Aranesp
Darbepoetin Alfa
Manufactured by Amgen
Jynarque
Tolvaptan
Manufactured by Otsuka
Aranesp costs 92% less per claim than Jynarque ($457.00 vs $5,919.00). A generic version of Aranesp is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aranesp | Jynarque |
|---|---|---|
| Avg Cost Per Claim | $457.00 | $5,919.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 86,000 | 12,000 |
| Total Claims | 1,240,000 | 148,000 |
| Annual Cost/Patient | $6,593.00 | $73,000.00 |
| Year-over-Year Change | -4.8% | +24.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Amgen | Otsuka |
| Condition | Kidney Disease | Kidney Disease |
| Generic Name | Darbepoetin Alfa | Tolvaptan |
Aranesp vs Jynarque: What the Data Shows
Aranesp (Darbepoetin Alfa) and Jynarque (Tolvaptan) are both used to treat kidney disease. Based on Medicare Part D data, Aranesp costs $457.00 per claim, which is 92% less than Jynarque at $5,919.00 per claim.
Medicare spent $567.0M on Aranesp and $876.0M on Jynarque. In terms of patient reach, Aranesp serves more beneficiaries (86,000 vs 12,000).
Year-over-year spending changed -4.8% for Aranesp and +24.6% for Jynarque. Jynarque saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Aranesp is cheaper at $457.00 per claim, compared to $5,919.00 for Jynarque. That makes Aranesp about 92% less expensive per claim based on Medicare Part D data.
Yes, both Aranesp and Jynarque are used to treat kidney disease. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Darbepoetin Alfa and generic Tolvaptan can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Aranesp covering 86,000 beneficiaries, and $876.0M on Jynarque covering 12,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.